Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD
PublisherBioMed Central Ltd.
MetadataShow full item record
AbstractBackground: The literature is scarce regarding the prevalence and clinical impact of IgG subclass deficiency in COPD. We investigated the prevalence of IgG subclass deficiencies and their association with exacerbations and hospitalizations using subjects from two COPD cohorts. Methods: We measured IgG subclass levels using immunonephelometry in serum samples from participants enrolled in two previous COPD trials: Macrolide Azithromycin for Prevention of Exacerbations of COPD (MACRO; n = 976) and Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE; n = 653). All samples were collected from clinically stable participants upon entry into both studies. IgG subclass deficiency was diagnosed when IgG subclass levels were below their respective lower limit of normal: IgG1 < 2.8 g/L; IgG2 < 1.15 g/L; IgG3 < 0.24 g/L; and IgG4 < 0.052 g/L. To investigate the impact of IgG subclass levels on time to first exacerbation or hospitalization, we log-transformed IgG levels and performed Cox regression models, with adjustments for confounders. Results: One or more IgG subclass deficiencies were found in 173 (17.7%) and 133 (20.4%) participants in MACRO and STATCOPE, respectively. Lower IgG1 or IgG2 levels resulted in increased risk of exacerbations with adjusted hazard ratios (HR) of 1.30 (95% CI, 1.10-1.54, p < 0.01) and 1.19 (95% CI, 1.05-1.35, p < 0.01), respectively in the MACRO study, with STATCOPE yielding similar results. Reduced IgG1 or IgG2 levels were also associated with increased risk of hospitalizations: the adjusted HR for IgG1 and IgG2 was 1.52 (95% CI: 1.15-2.02, p < 0.01) and 1.33 (95% CI, 1.08-1.64, p < 0.01), respectively for the MACRO study; in STATCOPE, only IgG2 was an independent predictor of hospitalization. In our multivariate Cox models, IgG3 and IgG4 levels did not result in significant associations for both outcomes in either MACRO or STATCOPE cohorts. Conclusions: Approximately 1 in 5 COPD patients had one or more IgG subclass deficiencies. Reduced IgG subclass levels were independent risk factors for both COPD exacerbations (IgG1 and IgG2) and hospitalizations (IgG2) in two COPD cohorts. Copyright 2018 The Author(s).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85042095858&doi=10.1186%2fs12931-018-0733-z&partnerID=40&md5=67cdf75ba3ab7bae5f6dfeafaac6adb4; http://hdl.handle.net/10713/9689
- Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations.
- Authors: Brown KE, Sin DD, Voelker H, Connett JE, Niewoehner DE, Kunisaki KM, COPD Clinical Research Network.
- Issue date: 2017 Oct 24
- Characterization of adult patients with IgG subclass deficiency and subnormal IgG2.
- Authors: Barton JC, Barton JC, Bertoli LF, Acton RT
- Issue date: 2020
- Serum IgG Levels and Risk of COPD Hospitalization: A Pooled Meta-analysis.
- Authors: Leitao Filho FS, Mattman A, Schellenberg R, Criner GJ, Woodruff P, Lazarus SC, Albert RK, Connett J, Han MK, Gay SE, Martinez FJ, Fuhlbrigge AL, Stoller JK, MacIntyre NR, Casaburi R, Diaz P, Panos RJ, Cooper JA Jr, Bailey WC, LaFon DC, Sciurba FC, Kanner RE, Yusen RD, Au DH, Pike KC, Fan VS, Leung JM, Man SP, Aaron SD, Reed RM, Sin DD
- Issue date: 2020 Oct
- Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease.
- Authors: Leitao Filho FS, Won Ra S, Mattman A, Schellenberg RS, Fishbane N, Criner GJ, Woodruff PG, Lazarus SC, Albert R, Connett JE, Han MK, Martinez FJ, Leung JM, Man SFP, Aaron SD, Reed RM, Sin DD
- Issue date: 2017 Oct
- Clinical and laboratory evaluation of periodically monitored Turkish children with IgG subclass deficiencies.
- Authors: Karaca NE, Karadeniz C, Aksu G, Kutukculer N
- Issue date: 2009 Mar